Hoechst Aktiengesellschaft

Gunter Regitz

Karl Geisen

Rudi Weyer

Volker Hitzel

What are disclosed are sulfonyl ureas of the formula ##STR1## in which R.sup.1, X and Y are as defined in the specification, and their physiologically acceptable salts, pharmaceutical formulations on the basis of these compounds, and their use in the treatment of diabetes.

Heterocyclic substituted sulfonyl ureas, and their use

Sulfonylureas of the formula ##STR1## in which ##STR2## R.sup.1, X and Y have the indicated meanings and the physiologically acceptable salts thereof, pharmaceutical preparations on the basis of said compounds and their use in the treatment of diabetes.

Benzenesulfonyl ureas, and pharmaceutical preparations

Sulfonylureas of the formula ##STR1## wherein R.sup.1, X and Y have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use in the treatment of diabetes.

Thienopyrrolone substituted benezenesulfonylureas and their use

Sulfonylureas of the formula ##STR1## wherein n, R, R.sup.1 and X have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use for treating diabetes.

Antidiabetic 1-piperidine-sulfonylureas

Sulfonylureas of the formula ##STR1## in which n, R, R.sup.1, X and Y have the indicated meanings and the physiologically acceptable salts thereof, pharmaceutical preparations on the basis of said compounds and their use in the treatment of diabetes.

Growing community of inventors

Bad Soden am Taunus, Germany

Gunter Regitz